TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$115.23 Million

IVERIC bio, Inc.

Follow-on Offering

Lead Left Bookrunner, July 2021

IVERIC bio, Inc.

IVERIC bio, Inc. is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.